Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 11/20 | 0.44 |
| ▸ | HTR2A | P28223 | 10/20 | 0.44 |
| ▸ | HTR1A | P08908 | 9/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22644615 | 0.90 | DRD2 (0.47) | SLC6A2SLC6A4DRD2HTR2AHTR1A | |
| SCHEMBL22638125 | 0.88 | KDM4E (0.51) | SLC6A2SLC6A4DRD2HTR2AHTR1A | |
| SCHEMBL22644667 | 0.86 | DRD4 (0.45) | HTR1ADRD4 | |
| SCHEMBL22644616 | 0.86 | CXCR3 (0.43) | DRD2HTR2AHTR1AKDM4EALDH1A1 | |
| SCHEMBL29749563 | 0.83 | DRD2 (0.40) | DRD2HTR2AHTR1AALDH1A1PDK2 | |
| SCHEMBL22644656 | 0.83 | GPR119 (0.47) | DRD2DRD4 | |
| SCHEMBL29749314 | 0.80 | HRH3 (0.42) | DRD4 | |
| SCHEMBL22638139 | 0.79 | FFAR4 (0.48) | FFAR4ALDH1A1HSD11B1 | |
| SCHEMBL22644660 | 0.79 | HTR1A (0.36) | DRD2HTR2AHTR1ADRD4PDK2 | |
| SCHEMBL29749666 | 0.79 | HTR1A (0.36) | DRD2HTR2AHTR1ADRD4PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325708-B2 | Adenosine 2 receptor antagonists | NEKTAR THERAPEUTICS (US) | 2025-06-10 | — | — | US | disclosed |
| US-20220235056-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | NEKTAR THERAPEUTICS | 2022-07-28 | — | — | US | disclosed |
| WO-2020227156-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | NEKTAR THERAPEUTICS (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235056-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA3 | SLC6A2 879/4885SLC6A4 1490/4885DRD2 466/4885 |
| US-12325708-B2 | Adenosine 2 receptor antagonists | ADORA2A, ADORA2B, ADORA3 | SLC6A2 879/4885SLC6A4 1490/4885DRD2 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.